Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1987 3
1988 4
1989 4
1990 3
1991 4
1992 1
1993 4
1994 3
1995 5
1996 2
1997 5
1998 4
1999 7
2000 8
2001 7
2002 6
2003 2
2004 3
2005 3
2006 8
2007 8
2008 9
2009 6
2010 14
2011 15
2012 18
2013 15
2014 25
2015 15
2016 17
2017 18
2018 6
2019 8
2020 18
2021 11
2022 11
2023 13
2024 8
2025 9
2026 3

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

304 results

Results by year

Filters applied: . Clear all
Page 1
Management of freezing of gait - mechanism-based practical recommendations.
Tosserams A, Fasano A, Gilat M, Factor SA, Giladi N, Lewis SJG, Moreau C, Bloem BR, Nieuwboer A, Nonnekes J. Tosserams A, et al. Among authors: factor sa. Nat Rev Neurol. 2025 Jun;21(6):327-344. doi: 10.1038/s41582-025-01079-6. Epub 2025 Apr 1. Nat Rev Neurol. 2025. PMID: 40169855 Review.
Safety and efficacy of valbenazine for the treatment of chorea associated with Huntington's disease (KINECT-HD): a phase 3, randomised, double-blind, placebo-controlled trial.
Furr Stimming E, Claassen DO, Kayson E, Goldstein J, Mehanna R, Zhang H, Liang GS, Haubenberger D; Huntington Study Group KINECT-HD Collaborators. Furr Stimming E, et al. Lancet Neurol. 2023 Jun;22(6):494-504. doi: 10.1016/S1474-4422(23)00127-8. Lancet Neurol. 2023. PMID: 37210099 Clinical Trial.
Deutetrabenazine for treatment of involuntary movements in patients with tardive dyskinesia (AIM-TD): a double-blind, randomised, placebo-controlled, phase 3 trial.
Anderson KE, Stamler D, Davis MD, Factor SA, Hauser RA, Isojärvi J, Jarskog LF, Jimenez-Shahed J, Kumar R, McEvoy JP, Ochudlo S, Ondo WG, Fernandez HH. Anderson KE, et al. Among authors: factor sa. Lancet Psychiatry. 2017 Aug;4(8):595-604. doi: 10.1016/S2215-0366(17)30236-5. Epub 2017 Jun 28. Lancet Psychiatry. 2017. PMID: 28668671 Clinical Trial.
Movement disorders emergencies.
Munhoz RP, Scorr LM, Factor SA. Munhoz RP, et al. Among authors: factor sa. Curr Opin Neurol. 2015 Aug;28(4):406-12. doi: 10.1097/WCO.0000000000000212. Curr Opin Neurol. 2015. PMID: 26110802 Review.
Randomized controlled trial of deutetrabenazine for tardive dyskinesia: The ARM-TD study.
Fernandez HH, Factor SA, Hauser RA, Jimenez-Shahed J, Ondo WG, Jarskog LF, Meltzer HY, Woods SW, Bega D, LeDoux MS, Shprecher DR, Davis C, Davis MD, Stamler D, Anderson KE. Fernandez HH, et al. Among authors: factor sa. Neurology. 2017 May 23;88(21):2003-2010. doi: 10.1212/WNL.0000000000003960. Epub 2017 Apr 26. Neurology. 2017. PMID: 28446646 Free PMC article. Clinical Trial.
304 results